The Changing Treatment Landscape for Metastatic Urothelial Carcinoma
This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Neuroendocrine and Adrenal Tumors, Version 2.2018
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies heavily on the site of the primary NET.
Category
  • Neuroendocrine Tumors
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 5.2018
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.
Category
  • Lung Cancers
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Colorectal Cancer Screening, Version 1.2018
The NCCN Guidelines for Colorectal Cancer (CRC) Screening outline various screening modalities as well as recommended screening strategies for individuals at average or increased-risk of developing sporadic CRC.
Category
  • Colorectal Cancer
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Task Force Report: Chimeric Antigen Receptor T-Cell Therapy
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Bladder Cancer, Version 5.2018
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer.
Category
  • Bladder Cancer
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Keynote Session: CAR T-cell Therapy - Focus on Lymphomas
Chimeric antigen receptor (CAR) T-cell therapy is a new and rapidly evolving immunotherapy emerging as a novel treatment option for relapsed or refractory lymphomas.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Keynote Session: CAR T-cell Therapy - Focus on Leukemia
Chimeric antigen receptor (CAR) T-cell therapy is an emerging immune-based therapy used in cancer treatment. It has demonstrated significant impact in the management of hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL).
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Keynote Session: CAR T-cell Therapy - Historical Perspectives and Major Milestones
Chimeric antigen receptor (CAR) T-cell therapy is an immune-based therapy used in cancer treatment that has demonstrated efficacy in the management of many hematologic malignancies, suggesting significant impact on oncology practice.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Consideration for Use of Novel Agents in Acute Myeloid Leukemia
There is a need for improved therapeutic strategies to combat AML disease progression.  Recent developments have expanded treatment options for acute myeloid leukemia (AML) including targeted agents, antibody-drug conjugates and novel formulations.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages